The 8% revenue decline and 15% RUCONEST® drop are concerning, but Joenja®'s 34% growth and reaffirmed full-year guidance suggest the company expects H2 acceleration. Watch for the European Commission decision on Joenja® (expected Q2 2026) and Phase II leniolisib readouts in H2 2026 as key catalysts. The positive operating cash flow and narrowing loss provide some cushion, but RUCONEST® erosion remains a risk.
Price Chart
Executive Summary
Pharming Group reported Q1 2026 total revenues of $72.4M, an 8% decline YoY, driven by a 15% drop in RUCONEST® revenue ($58.4M) due to inventory drawdowns and market exits. Joenja® revenue grew 34% to $14.1M, and the company reaffirmed full-year 2026 revenue guidance of $405M-$425M (8%-13% growth). The net loss narrowed to $5.2M from $14.9M a year ago, and operating cash flow turned positive at $2.0M.
Key Financial Metrics
Key Facts
- Q1 2026 total revenues $72.4M, down 8% YoY from $79.1M
- RUCONEST® revenue $58.4M, down 15% YoY due to inventory drawdowns and non-U.S. market exit
- Joenja® revenue $14.1M, up 34% YoY, driven by U.S. patient growth (127 on paid therapy, +25% YoY)
- Net loss narrowed to $5.2M from $14.9M in Q1 2025
- Positive net cash flow from operations of $2.0M vs $0.2M in prior year
- Reaffirmed FY2026 revenue guidance $405M-$425M (8%-13% growth)
- Joenja® approved in Japan for APDS patients aged 4+; positive CHMP opinion in Europe
- Resubmitted pediatric sNDA to FDA for Joenja® 40mg/50mg doses; additional sNDA planned for summer
- Cash and equivalents $171.8M at quarter end, down from $181.1M due to $12.3M lease settlement
Financial Impact
Revenue decline of $6.6M YoY (8%) with net loss improvement of $9.7M; positive operating cash flow of $2.0M
Risk Factors
- Continued RUCONEST® revenue decline from competitive dynamics and market exit
- FDA CRL on pediatric sNDA for Joenja® could delay label expansion
- Pipeline execution risk for napazimone (KL1333) and leniolisib Phase II trials
- Currency translation losses ($5.0M OCI loss in Q1) impacting reported results
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289568 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers